title: Nucleus accumbens core acetylcholine is preferentially activated during acquisition of drug- vs food-reinforced behavior.
abstract: Acquisition of drug-reinforced behavior is accompanied by a systematic increase of release of the neurotransmitter acetylcholine (ACh) rather than dopamine, the expected prime reward neurotransmitter candidate, in the nucleus accumbens core (AcbC), with activation of both muscarinic and nicotinic ACh receptors in the AcbC by ACh volume transmission being necessary for the drug conditioning. The present findings suggest that the AcbC ACh system is preferentially activated by drug reinforcers, because (1) acquisition of food-reinforced behavior was not paralleled by activation of ACh release in the AcbC whereas acquisition of morphine-reinforced behavior, like that of cocaine or remifentanil (tested previously), was, and because (2) local intra-AcbC administration of muscarinic or nicotinic ACh receptor antagonists (atropine or mecamylamine, respectively) did not block the acquisition of food-reinforced behavior whereas acquisition of drug-reinforced behavior had been blocked. Interestingly, the speed with which a drug of abuse distributed into the AcbC and was eliminated from the AcbC determined the size of the AcbC ACh signal, with the temporally more sharply delineated drug stimulus producing a more pronounced AcbC ACh signal. The present findings suggest that muscarinic and nicotinic ACh receptors in the AcbC are preferentially involved during reward conditioning for drugs of abuse vs sweetened condensed milk as a food reinforcer.
authors.affiliation: Experimental Psychiatry Unit, Department of Psychiatry, Medical University Innsbruck, Innsbruck, Austria.
authors.forename: Jose A
authors.initials: JA
authors.lastname: Crespo
authors.forename: Petra
authors.initials: P
authors.lastname: Stöckl
authors.forename: Katja
authors.initials: K
authors.lastname: Zorn
authors.forename: Alois
authors.initials: A
authors.lastname: Saria
authors.forename: Gerald
authors.initials: G
authors.lastname: Zernig
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D018680:Cholinergic Antagonists / Q000494:pharmacology; D003042:Cocaine / Q000494:pharmacology; D003213:Conditioning, Psychological / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D005247:Feeding Behavior / Q000502:physiology*; D007858:Learning / Q000187:drug effects / Q000502:physiology*; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D010880:Piperidines / Q000494:pharmacology; D017729:Presynaptic Terminals / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000378:metabolism; D012054:Reinforcement, Psychology; D000077208:Remifentanil; D019966:Substance-Related Disorders / Q000378:metabolism* / Q000503:physiopathology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
chemical_list: D018680:Cholinergic Antagonists; D010880:Piperidines; D011950:Receptors, Cholinergic; D009020:Morphine; D003042:Cocaine; D000109:Acetylcholine; D000077208:Remifentanil; D004298:Dopamine